The effect of the 6-month report was not what the company was waiting for because the results were only partial. It could be that we get more convincing results in future meetings or perhaps something new that we cannot expect now.
Last year ATH made presentations at these meetings (below) including the corresponding starting time this year:
1. Movement disorder conference in PA, USA, starting September 27th.
2. Neuroscience 2024, Chicago, starting October 5th
3. Autonomic nervous system conference, Santa Barbara, USA, starting November 6th.
I would think that all 10 patients have passed the 6-month examinations by the end of September and there will be more 12-month follow-ups. Perhaps these results are not presented in these meetings but in separate info presentations for investors. Even more important is that ATH will get new info to the potential Big Pharma companies to make a cooperation deal. Without a cooperation deal, it is difficult to understand how to get forward in January.
ATH Price at posting:
0.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)